Damascus Hospital
Damascus, +963, Syria
NCT Number: NCT03163680
Determining the efficacy of low dose of PPI in management acute peptic ulcer bleeding
Looking for future studies?
Notify Me18 year–90 year
All sexes
Observational
Damascus, +963, Syria
Determining the efficacy of low dose meaning 40 mg of omeprazole twice in management acute peptic ulcer bleeding
Only the study team can determine whether someone qualifies for participation.
Criteria:
Inclusion criteria
High risk ulcers defined according to the Forrest classification With respect to high-risk stigmata, active bleeding was defined as a continuous blood spurting (Forrest IA) oozing (Forrest IB) from the ulcer base. A non-bleeding visible vessel at endoscopy was defined as a discrete protuberance at the ulcer base(Forrest IIA).
An adherent clot was one that was resistant to forceful irrigation or suction (Forrest IIB).
Exclusion criteria
ulcer was malignant non ulcerative bleeding such as angiodysplasia , a Mallory-Weiss tear
Omperazole 40 mg twice daily
Time frame: within 1 week
Determination of mortality rate from ulcer bleeding
Time frame: within 1 week
Determination of the percentage of the return of bleeding represented by recurrent melena (black, tarry stool) or recurrent Hematemesis or coffee-ground emesis or recurrent hematochezia after begin treatment
Time frame: within 1 week
Determine the Surgery rate for treatment Bleeding ulcers within a week
Time frame: within 1 month
Determining the length of stay in the hospital
Time frame: within 1 week
number of transfusion blood unites during admission
Damascus Hospital
Other
Efficacy of Low Dose of Proton Pumb Inhabitor in Treatment Upper Gastrointestinal Bleeding
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02175186
Digestive System Diseases, Duodenal Diseases
Seoul, Songpa-Gu, South Korea
View Trial DetailsNCT00778193
Digestive System Diseases, Duodenal Diseases
New York, United States
View Trial DetailsNCT05248321
Digestive System Diseases, Duodenal Diseases
Tainan, NONE Selected, Taiwan
View Trial DetailsNCT04211194
Digestive System Diseases, Duodenal Diseases
Orlando, Florida, United States
View Trial Details